Related references
Note: Only part of the references are listed.Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Michael Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
Thomas E Lew et al.
Lancet Haematology (2023)
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Yuqin Song et al.
BLOOD (2022)
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
Thomas E. Lew et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience
Antonio Gutierrez et al.
CANCERS (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio et al.
LEUKEMIA (2022)
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
Martin Dreyling et al.
BLOOD (2022)
Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
Adrian Minson et al.
BLOOD (2022)
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
Martin Dreyling et al.
HEMASPHERE (2022)
Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
Tycel Phillips et al.
BLOOD (2021)
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease
Thomas E. Lew et al.
BONE MARROW TRANSPLANTATION (2021)
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
Pashna N. Munshi et al.
BONE MARROW TRANSPLANTATION (2021)
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
Mauricette Michallet et al.
BONE MARROW TRANSPLANTATION (2020)
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song et al.
CLINICAL CANCER RESEARCH (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
p53 is associated with high-risk and pinpointsTP53missense mutations in mantle cell lymphoma
Joana M. Rodrigues et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma
Ales Obr et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
Preetesh Jain et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
Toby A. Eyre et al.
HAEMATOLOGICA (2019)
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma
Simon Rule et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
Sasanka M. Handunnetti et al.
BLOOD (2019)
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Simon Rule et al.
HAEMATOLOGICA (2019)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network
Sietse M. Aukema et al.
BLOOD (2018)
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
S. Le Gouill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Christian W. Eskelund et al.
BLOOD (2017)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Christian W. Eskelund et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
A. M. Halldorsdottir et al.
LEUKEMIA (2011)
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Constantine S. Tam et al.
BLOOD (2009)
Share Paper
